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Abstract
Introduction: Expression levels of miR-146b-5p and -3p microRNAs in human non-small cell lung cancer (NSCLC) are
associated with recurrence of the disease after surgery. To understand this, the effect of miR-146b overexpression was
studied in A549 human lung cancer cells.
Methods: A549 cells, engineered with lentiviruses to overexpress the human pre-miR-146b precursor microRNA, were
examined for proliferation, colony formation on plastic surface and in soft agar, migration and invasiveness in cell culture
and in vivo in mice, chemosensitivity to cisplatin and doxorubicin, and global gene expression. miR-146b expressions were
assessed in microdissected stroma and epithelia of human NSCLC tumors. Association of miR-146b-5p and -3p expression in
early stage NSCLC with recurrence was analyzed.
Principal Findings: A549 pre-miR-146b-overexpressors had 3–8-fold higher levels of both miR-146b microRNAs than control
cells. Overexpression did not alter cellular proliferation, chemosensitivity, migration, or invasiveness; affected only 0.3% of
the mRNA transcriptome; and, reduced the ability to form colonies in vitro by 25%. In human NSCLC tumors, expression of
both miR-146b microRNAs was 7–10-fold higher in stroma than in cancerous epithelia, and higher miR-146b-5p but lower -
3p levels were predictive of recurrence.
Conclusions: Only a minimal effect of pre-miR-146b overexpression on the malignant phenotype was seen in A549 cells. This
could be because of opposing effects of miR-146b-5p and -3p overexpression as suggested by the conflicting recurrence-
predictive values of the two microRNAs, or because miR-146b expression changes in non-cancerous stroma and not
cancerous epithelia of tumors are responsible for the prognostic value of miR-146b.
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Introduction
MicroRNAs are ultrashort non-coding RNAs that regulate
cellular processes by their sequence-specific influence on the
stability and translation of multiple messenger RNAs (mRNAs).
Studies over the past few years have shown the importance of these
epigenetic regulatory molecules in cancer biology [1] as well as
their utility as biomarkers of disease states [2]. We previously
quantified the expression of microRNAs in 77 human stage I non-
small cell lung cancer (NSCLC) tumors to identify microRNAs
whose levels are associated with recurrence of the disease following
surgical resection [3]. Expression of miR-146b microRNAs, miR-
146b-5p and miR-146b-3p, in the tumors differed significantly
between cases that had a recurrence and those that did not, with
the mean miR-146b-5p level higher but the mean miR-146b-3p level
lower in the former group. Furthermore, in internal cross-
validations, miR-146b-3p was identified as a frequent constituent
of six-microRNA support vector machines classifiers that could
predict recurrence with a mean accuracy of 69%. Higher
expression of miR-146b-5p in human tumors was also found to
be associated with poor overall survival in stage I-III NSCLC in a
study that focused on the squamous cell variety of the disease but
did not examine miR-146b-3p [4]. Besides lung cancer, a higher
level of miR-146b-5p in tumors is also associated with a more
malignant disease in human papillary thyroid carcinoma [5].
In humans, both miR-146b-5p and -3p microRNAs are products
of the same MIR146B gene that is located on chromosome 10 at
position q24.32. Like most pairs of 5p and 3p microRNAs, the two
miR-146b microRNAs are generated from the opposite strands (the
59 and 39 arms) of a double-stranded stem region of a precursor
microRNA, pre-miR-146b, which in turn is derived from the
primary MIR146B RNA transcript [6]. The expression of miR-
146b-5p appears to be ubiquitous in human tissues, though higher
levels are seen in lung, thymus and spleen [7]. Small RNA cloning
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in cells is much less than that of miR-146b-5p [8,9]. Such a
difference is seen for many 5p and 3p microRNA pairs, which
constitute a majority of microRNAs. This strand bias is believed to
be a result of thermodynamic effects on microRNA processing
dictated by the microRNA sequences [10,11] as well as the levels
of target mRNAs in the cellular environment [12,13]. Even
though one of the 5p and 3p microRNAs may be much less
abundant than the other (and often referred to as the ’microRNA*’
species), it can have significant influence on the cellular state
[14,15]. It should be noted that the nature of strand bias can vary
spatiotemporally. For example, the miR-202/miR-202* expression
ratio changes from ,0.5 to ,0.9 during female gonadogenesis in
chicken embryos [16], and mouse miR-194-5p is present at a
higher level than miR-194-3p in kidney and stomach, but at a
lower level in lung and uterus [17].
A number of studies have examined the role of miR-146b
microRNAs in cancer ceIl-lines. In a study of U373 human
glioblastoma cells, invasiveness and migration was decreased by
overexpression of the microRNAs and increased by their
knockdown using antisense oligonucleotides, and the targeting of
transcripts of the MMP16 matrix metalloproteinase gene by miR-
146b-5p was identified [18]. In vitro migration and invasion of
another human glioblastoma cell-line, U87-MG, has also been
shown to be reduced by miR-146b-5p overexpression [19]. The
microRNA was shown to target transcripts of the EGFR gene
encoding epidermal growth factor receptor. EGFR-targeting by
miR-146b-5p has also been shown in MDA-MB-231 human breast
cancer cells [20]. As in the glioblastoma studies, pre-miR-146b
overexpression in the cells reduced thier migration and invasive-
ness [20]. Similar findings were reported in another study which
also suggested a role for miR-146b-5p in negatively regulating the
nuclear factor-kB (NF-kB) pathway [21]. Such functional studies
have not been performed in lung cancer cells. To understand the
association of the miR-146b microRNAs with lung cancer
prognosis, we sought to study the effects of overexpressing the
pre-miR-146b precursor microRNA on the malignant phenotype of
the A549 lung adenocarcinoma cell-line.
Materials and Methods
Ethics statement
All research presented here was approved by the Institutional
Review Board of the Roswell Park Cancer Institute (RPCI). All
animal experiments were performed after approval by RPCI’s
Institute Animal Care and Use Committee under protocol number
1132M.
Cell culture
A549 human lung adenocarcinoma and BEAS-2B normal
human bronchial epithelial cell-lines were obtained from ATCCH
(Manassas, VA). TLA-HEK293T
TM, a human embryonic kidney
cell-line derived from the 293T cell-line, was obtained from Open
BiosystemsH (Huntsville, AL). A549 and TLA-HEK293T
TM cells
were cultured at 37uC in 90% humidity and 5% CO2 in
Dulbecco’s modified Eagle medium (+DMEM; MediatechH,
Manassas, VA) with 10% fetal bovine serum (PAA LaboratoriesH,
Pasching, Austria) in a Steri-Cult
TM incubator (Thermo Fisher
ScientificH, Waltham, MA). LHC-9 medium (InvitrogenH, Carls-
bad, CA) was used for BEAS-2B cells. Cell-lines generated in this
study were cultured in the presence of 2 mg/ml puromycin
(RocheH, Indianapolis, IN). Cells were harvested using 0.05%
trypsin with 0.25 mM ethylene-diamine-tetraacetic acid (Invitro-
genH). Cells were not cultured for more than six weeks, and
concurrently-cultured and similarly-aged cells were used when
comparing cell-lines. Maintenance cultures at semi-confluence
were used to set up experiments. A Scepter
TM electronic counter
(MilliporeH, Billerica, MA) or disposable hemacytometer slides
(IncytoH, Dusseldorf, Germany) were used to measure cell-
densities of re-suspended cells.
Generation of stably-transduced cell-lines
Complementary, single-stranded DNA oligonucleotides with the
human pre-miR-146b sequence (miRBase [22] accession number
MI0003129) and restriction enzyme-site overhangs were obtained
from Integrated DNA TechnologiesH (Coralville, IA). Oligonucle-
otides were also obtained for a variant sequence in which the
segments for the miR-146b-5p and -3p microRNAs were swapped.
After annealing to generate double-stranded DNA, the oligonucle-
otides were ligated to Xho I- and Not I (InvitrogenH)-digested
pLemiR
TM vector (Open BiosystemsH). TOP10
TM competent E.
coli (InvitrogenH) were heat-transformed with the ligation products.
Plasmid DNA was prepared from cultures of selected single clones
using a kit supplied by QiagenH (Valencia, CA). Identity of plas-
mids was confirmed by DNA sequencing at a core facility at the
Roswell Park Cancer Institute in Buffalo, NY (RPCI). En-
gineered lentiviruses were prepared by transfecting plasmids into
TLA-HEK293T
TM cells using reagents and protocols provided
with the Trans-Lentiviral GIPZ
TM packaging system (Open
BiosystemsH). A549 cells were transduced with viruses for 48 hours
and then subjected to selection against 2 mg/ml puromycin for
about two weeks to generate cell-lines A549/vec, A549/146b, and
A549/v146b, using viruses generated with an empty pLemiR
TM
vector, or with the vector bearing the natural or the variant pre-miR-
146b sequence, respectively.
Flow cytometry
Flow cytometry of freshly-harvested cells stained with 1 mg/ml
of the 7-amino-actinomycin D viability dye (SigmaH, St. Louis,
MO) was performed on a FACSCalibur machine (BD Bioscien-
cesH, San Jose, CA). Forward- and side-scatter, and fluorescence in
the FL2 and FL4 channels were recorded for 10,000 events, and
FL2 fluorescence values were plotted after gating out dead cells
with the CellQuest
TM Pro software (version 5; BD BiosciencesH).
Cell proliferation assay
Cell proliferation assays were performed using the Cell
Counting Kit-8 assay (CCK-8; Dojindo Molecular TechnologiesH,
Rockville, MD) which uses the bioreduction of 2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H tetrazoli-
um sodium (WST-8) to orange-colored formazan to measure cell
viability. Briefly, 100 ml of cells at 2-4x10
4/ml cells were plated on
96-well culture plates. At various time-points over the next four
days, the culture medium in quadruplicate wells was replaced with
fresh medium containing 5% CCK-8 reagent, and after an hour,
absorbance at 450 nm was measured on a Multiskan Plus (MTX
Lab SystemsH, Vienna, VA) plate reader. Absorbance values were
corrected by subtracting those of control wells that did not have
cells.
Drug sensitivity assay
Cells were grown to 50%-60% confluence in 96-well culture
plates in quintuplicate when the culture medium was replaced with
that containing 0.5–2.0 mg/ml of either doxorubicin hydrochloride
(Enzo Life SciencesH, Farmingdale, NY) or cisplatin (CalbiochemH,
SanDiego,CA)orneither.Aftertwodaysofculture,viabilityofcells
was measured as described for the cell proliferation assay.
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For adherent colony formation assays, 200 cells were plated per
35 mm-culture dish in triplicate and cultured with medium
changes every 4–5 days. After 10–14 days, dishes were stained
with 0.2% methylene blue in 40% methanol for 30 minutes. For
colony formation in soft agar, a dish was first coated with 1.5 ml
medium containing 0.7% agar (SigmaH) before cells, in 2 ml
medium containing 0.35% agar, were added at 150 cells/dish.
After polymerization of agarose in about 15 minutes, 2 ml of
medium was added. Cells were cultured for 6–7 weeks with
medium change every 4–5 days, and then stained with 2 mg/ml
thiazolyl blue tetrazolium bromide (SigmaH) for 4–8 hours in the
cell culture incubator. Stained dishes were scanned on a Perfection
V700 (EpsonH, Long Beach, CA), and a minimum area on images
corresponding to 3778 or 199 mm
2, respectively for the adherent
and soft agar colony assays, was used for identifying colonies for
quantification using ImageJ
TM software (version 10.2; National
Institute of Mental Health, Bethesda, MD).
In vitro wound healing assay
Six-well culture plates were marked with a cross-hair pattern on
the outside surface of their bottoms. Cells were then plated in
triplicate at a high density to reach 100% confluence a day later,
when an approximately 2 cm-long and 0.5 mm-wide wound was
made by dragging a plastic 10 ml pipette-tip along a straight edge
with moderate and consistent pressure to scratch the cell mono-
layer. The culture medium was then replaced. Cells were imaged
immediately and after a day of culture at 50x magnification at the
same locations along the scratches.
Transwell
TM migration and invasion assays
Twenty-four-well Transwell
TM plates with a polycarbonate
membrane and an 8 mm pore-size were obtained from CorningH
(Corning, NY). Semi-confluent cells that had been starved for 16–
20 hours by culture in serum-free +DMEM medium were
harvested from 10 cm-culture dishes, washed twice with phos-
phate-buffered isotonic saline (PBS; 137 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4 and 1.76 mM KH2PO4 at pH 7.4), and
re-suspended in serum-free +DMEM medium at 2–3610
5
cells/ml. Cells were plated in triplicate in 0.1 ml of +DMEM
per Transwell
TM, with bottom wells containing 0.6 ml +DMEM
medium with 15% fetal bovine serum. The same volume of cell
suspensions were concurrently plated in triplicate in wells of 24-
well culture plates for indirectly assessing cell density by
measuring cell viability after 8–16 hours as described for cell
proliferation assay. For invasion assays, the Transwell
TM
membranes were pre-coated with either Cultrex
TM PathClear
TM
basement membrane extract prepared from murine Engelbreth-
Holm-Swarm tumor cells, or collagen I from rat tails (TrevigenH,
Gaithersburg, MD). Coating was performed by layering 50 mlo f
the proteins at 1.5 mg/ml and 50 mg/ml, respectively, in serum-
free +DMEM medium and allowing the layers to dry under 90%
humidity at 37uC for 1 hour and 16–24 hours, respectively.
Dried layers were rinsed thrice with serum-free +DMEM
medium before cells were plated. After 8 or 16–20 hours,
respectively, for the migration or invasion assays, upper surfaces
of the Transwell
TM membranes were wiped with cotton swabs to
remove non-migrated cells. In the migration assay, cells
remaining in the membranes were fixed with 10% neutral
buffered-formalin and stained overnight with 0.2% w/v crystal
violet (SigmaH) in 2% ethanol. After thorough washing with water
to remove any unincorporated dye, 300 ml of 10% acetic acid was
added to each Transwell
TM to extract bound dye by shaking the
wells at 100 revolutions/minute for 20 minutes. Extracts were
analyzed for absorbance at 595 nm using 10% acetic acid as
reference. In the invasion assays, red fluorescence images of cells
in the Transwell
TM membranes were acquired at 50x magnifi-
cation in three different field-views. The absorbance readings or
the average number of cells per field was normalized using the
cell viability measurements of the cells that had been concurrently
plated in separate cultures.
Pulmonary tumor formation assay
This work was approved by various institutional committees at
RPCI. Cells grown to about 70% confluence were harvested by
trypsinization for three minutes, washed with PBS, and re-
suspended in ice-cold +DMEM at 5610
6 cells/ml. An expert
technician used a 1 ml-syringe with a 27 G needle to inject 0.2 ml
of cells in the tail vein of immunodeficient, female, 6–10 week-old
mice of C.B-Igh-1
b/lcrTac-Prkdc
scid/Ros strain. Mice were moni-
tored twice weekly for labored breathing as well as for general
malaise and any visible appearance of a cancerous lesion or
growth, and euthanized after 12 weeks even though none of the
mice had any of these symptoms or signs. Lungs were removed,
washed with PBS, fixed for a day with 10% neutral buffered-
formalin, and weighed after dabbing off excess liquid with paper
towels.
Laser capture microdissection (LCM)
This work was approved by an institutional review board at
RPCI, and performed under the supervision of a pathologist in
the Department of Pathology of RPCI on tissues from 12 cases of
stage I NSCLC that had been treated at the institute. Formalin-
fixed, paraffin-embedded, 6–8 mm-thick tissue-sections with at
least 70% tumor tissue as verified by histological examination
by a pathologist were used. Tissue-sections were placed on
glass slides coated with a polyethylene naphthalate membrane
(LeicaH, Wetzlar, Germany) and dried overnight at room tem-
perature. After de-paraffinization with xylene followed by
gradual rehydration overnight using graded alcohols, the slides
were stained with hematoxylin and eosin, and air-dried
overnight. LCM was performed on an LMD6000 system
(LeicaH) at 200x magnification with laser power, speed and
specimen-balance settings of 80, 2 and 11, respectively. Tumor-
containing regions on the sections were identified by the altered
cellular morphology of cancerous epithelial cells. Stromal and
cancerous epithelial components of such regions were microdis-
sected and collected in separate 0.5 ml tubes. For each




cell-sections) were collected. The stromal-to-epithelial area ratio
varied from about 0.6 to 1.
Isolation of RNA
Silica columns, reagents and protocols provided with the
Purelink
TM RNA (InvitrogenH), or High Pure
TM microRNA
(RocheH) and FFPE RNA (Norgen BiotekH, Thorold, Canada)
kits, respectively, were used to isolate total from 2–5610
6 cultured
cells or from proteinase K-treated microdissected cells. Nucleic
acid concentration in the preparations was estimated by
absorbance spectrophotometry on Ultrospec II (LKB BiochromH,
Cambridge, UK) or NanoDrop
TM 1000 (Thermo Fisher Scienti-
ficH) instruments. A fluorometric assay using Quant-iT
TM Ribo-
green (InvitrogenH) was used to quantify nucleic acids in the
preparations from the microdissected cells. Total RNA from
MCF-7 human breast cancer and ML-2 human acute myeloid
leukemia cells were kindly provided by, respectively, the research
groups of Drs. Gokul Das and Eunice Wang of RPCI.
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transcription-PCR (RT-PCR)
Semi-quantification of human microRNAs let-7a, miR-30a-5p,
miR-146b-5p and miR-146b-3p, and the small nucleolar RNA
RNU6B was done with RT-PCR-based TaqMan
TM MicroRNA
Assays (Applied BiosystemsH, Foster City, CA; assay IDs 377, 417,
1097, 2361 and 1093, respectively). Briefly, an RNA-specific
oligonucleotide, and reagents provided with the TaqMan
TM
MicroRNA Reverse Transcription Kit (Applied BiosystemsH) were
used to reverse transcribe 10 ng total RNA from cells, or 5 mlo f
0.5-2000 fM synthetic mature microRNAs miR-146b-5p and -3p
with 59 phosphate and 39 hydroxyl terminii obtained from
InvitrogenH. The cDNA was used as template in 40 cycle-PCR
reactions on a 7900HT real-time PCR machine (Applied
BiosystemsH). For each reaction, the quantification cycle (Cq)
value, approximately inversely proportional to log2 value of the
concentration of the analyte RNA, was obtained with SDS
TM
software (Applied BiosystemsH; version 2.3). The average of Cq
values of triplicate PCR reactions was used for analysis. When
needed, Cq values for microRNAs were normalized by subtracting
the value for the small nucleolar RNU6B RNA.
Gene expression analysis using BeadChip
TM technology
Total RNA, isolated from A549/vec and A549/146b cells in
two experiments for biological duplication, was provided to the
shared gene expression facility of RPCI for analyses. Absorbance
spectrophotometry and electrophoresis on NanoDrop
TM 1000 and
Bioanalyzer
TM 2100 (Agilent TechnologiesH, Santa Clara, CA),
respectively, showed that the RNA preparations had 260 nm/
280 nm absorbance ratios in the 1.9–2.0 range, 260 nm/230 nm
absorbance ratios .1.8, and RNA integrity numbers .7.
IlluminaH TotalPrep RNA Amplification kit (AmbionH, Autin,
TX) was used to convert 500 ng of RNA to cDNA, which was
then transcribed in vitro to generate biotin-labeled RNA.
Hybridization reagents were mixed with 750 ng of labeled RNA,
and the mixture was hybridized overnight at 58uC to HumanRef-8
v3.0 Expression BeadChips
TM array (IlluminaH, San Diego, CA)
that has probes to detect 24,526 annotated human transcripts.
Following washing and staining with Cy3 dye-labeled streptavidin,
BeadChips
TM were imaged using the BeadArray Reader (Illumi-
naH). Data was acquired with GenomeStudio
TM software (version
2010.1; IlluminaH), and then processed for background-correction,
variance-stabilizing transformation, and then robust splines-
normalization between arrays using the lumi Bioconductor
package (version 1.14) for R language (version 2.11.1) with default
settings. Raw and processed data can be found in the NCBI Gene
Expression Omnibus repository with accession number
GSE29496. Good quality of the data was confirmed by examine
different aspects of data as recommended by IlluminaH. Multi-
testing with a paired t test with moderated t statistics and
Benjamini-Hochberg correction for false discovery rate was done
on the processed data using the limma Bioconductor package
(version 3.4.5).
Other
An EOS 450D digital camera (CanonH, Lake Success, NY) and
an Axio
TM Observer microscope (ZeissH, Maple Grove, MN) were
used for microphotography. Unless specified otherwise, chemicals
were procured from SigmaH or Thermo Fisher ScientificH. RNA
secondary structure prediction using mfold [23] with default
settings was performed online at http://mfold.rna.albany.edu.
Statistical analyses and graph plotting were done with Prism
TM
software (version 5.0c; GraphPad SoftwareH, La Jolla, CA). All t
tests were two-tailed, assumed equal variances, and used 0.05 as
the cut-off for deciding significance.
Results
Generation of A549 cell-lines overexpressing miR-146b
microRNAs
To study the effect of miR-146b overexpression in lung cancer
cells, human A549 lung adenocarcinoma cells were engineered to
overexpress the human pre-miR-146b precursor microRNA. The
pLemiR
TM lentiviral vector, which bears a gene for puromycin
resistance, was modified by inserting DNA for the pre-microRNA
sequence in the 39 untranslated region of the gene encoding for the
TurboRFP red fluorescent protein and driven by the constitutively
active cytomegalovirus (CMV) promoter. Following transduction
with lentiviruses, and puromycin selection, a stable population of
cells named A549/146b was generated. The A549/vec cell-line
was generated using pLemiR
TM vector without an insert. A549/
v146b cells were generated using the vector with a variant human
pre-miR-146b sequence. In the variant, the nucleic acid segments
corresponding to the miR-146b-5p and -3p microRNA sequences
were swapped (figure 1A) with the idea that the variation might
result in a relatively higher expression of miR-146b-3p, since,
among human microRNAs, those generated from the 5p arms of
pre-microRNAs tend to be expressed more than those from the 3p
arms [11]. The mfold [23] RNA-folding algorithm predicts that
like natural pre-miR-146b, the variant pre-microRNA too has a
stem-loop form (figure 1A), with a DGo f231.9 kcal/mol which is
5.2 kcal/mol more than that of the natural pre-microRNA.
Strong and stable expression of the pre-microRNA-bearing
TurboRFP gene in .90% of cells of each cell-line was confirmed
by fluorescence flow cytometry (figure 1B and data not shown).
Multiple cellular RNA preparations were assayed for miR-146b-5p
and -3p mature microRNAs by RT-PCR. Overexpression of the
miR-146b microRNAs was observed in both A549/146b and
A549/v146b cell-lines (figure 1C). Compared to A549/vec, miR-
146b-5p and -3p expression, normalized to that of the 45 base-
long, housekeeping small nucleolar RNA gene RNU6B, were
respectively an average of 4.9- and 6.6-fold higher in A549/146b
cells. In A549/v146b, they were respectively an average of 2.6-
and 6.5-fold higher, suggesting the variant pre-microRNA
expressed by it was processed into mature miR-146b-5p and -3p
microRNAs. To more accurately quantify the effect of the
variation on the ratio of amounts of miR-146b-5p and -3p in the
cells, synthetic miR-146b-5p and -3p RNAs were used to generate
standard curves to examine the relationship between RT-PCR
measurements (Cq values) and RNA amounts. Though assays for
both microRNAs had similar RT-PCR kinetics, with each log2
unit change in RNA input producing approximately a unit change
in the Cq value over a dilution range of 12 log2 units, the sensitivity
of the miR-146b-5p assay was higher by approximately 3.6 Cq units
(figure 1D). Therefore, miR-146b-3p Cq values were adjusted by
subtracting 3.6 in order to compare the amounts of miR-146b-5p
and -3p RNAs. In all the three A549-derived cell-lines, miR-146b-
5p microRNA was present at an amount that was about 4-6-fold
higher than that of the -3p microRNA (figure 1E). The variation in
the pre-microRNA sequence was found to have no significant
effect on the ratio of amounts of miR-146b-5p and -3p in the A549/
v146b cells compared to the A549/146b cells. Examination of
RNA from the human 293T embryonic kidney, BEAS-2B normal
bronchial, MCF-7 breast cancer, and ML-2 acute myeloid
leukemia cells, indicated that in these cell-lines too, miR-146b-5p
is present at a 4–22-fold higher molar excess than -3p (figure 1E).
Thus, the mature microRNA generated from the 5p strand of
miR-146b Overexpression in Lung Cancer Cells
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from the 3p strand, as suggested by other studies [8,9]. Expression
of miR-146b-5p in 293T, BEAS-2B, MCF-7 and ML-2 cells was
23.8-, 0.7-, 0.6- and 2.8-fold of that in A549/vec.
Overexpression of miR-146b microRNAs has only a minor
effect on the A549 cell phenotype
The A549-derived cell-lines were examined to identify an effect
of miR-146b overexpression on the A549 cells. Cell viability
measurements over time suggested that, compared to A549-vec,
both A549/146b and A549/v146b proliferated similarly in cell-
culture (figure 2A). Increased miR-146b levels did not seem to affect
the sensitivity of the cells to either cisplatin or doxorubicin at drug
concentrations varying from 0.5 to 2 mg/ml, even though the drugs
were clearly cytotoxic to the cells at the highest concentration
(figure 2B). Both are anti-cancer drugs that are used for treating
NSCLC. However, with the overexpression of the microRNA, both
A549/146b and A549/v146b cells formed only 80% and 65%,
Figure 1. Generation of A549-derived cell-lines. A. Most stable mfold-predicted secondary structures of human pre-miR-146b and a variant pre-
microRNA examined in this study. The 59 and 39 ends, nucleotide positions, and segments corresponding to mature miR-146b-5p and -3p sequences
(5p and 3p) are indicated. B. Histograms for red fluorescence quantified by flow cytometry of A549 and A549-derived cell-lines stably transduced with
lentiviruses bearing constructs engineered for expression of human pre-miR-146b (A549/146b), or its variant shown in A (A549/v146b), or neither
(A549/vec). C. Comparison of miR-146b-5p and -3p levels (5p and 3p), normalized to that of the RNU6B small nucleolar RNA, in the A549-derived cell-
lines as assessed using reverse transcription followed by PCR (RT-PCR). Means and their standard errors for measurements from three different
experiments are shown. D. Standard curves showing the relationship between quantification cycle (Cq) value and concentration of RNA in miR-146b-
5p and -3p (5p and 3p) RT-PCR assays of synthetic miR-146b-5p and -3p RNA, respectively. A log2 scale is used for the X axis. E. Semi-quantification of
the relative amounts of miR-146b-5p and -3p in RNA of 293T, BEAS-2B, MCF-7, and ML-2 (means, single experiments), and the three A549-derived cell-
lines, (means and their standard errors for measurements from three different experiments) are shown.
doi:10.1371/journal.pone.0022379.g001
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cells in adherent cell culture on the plastic surface of tissue culture
plates (t test P values of 0.04 and ,0.01, respectively). As expected
from the result of the proliferation assay showed in figure 2A, the
colonies formed by A549/146b and A549/v146b were not
significantly different in size than the ones formed by A549/vec (t
test P values of .0.05; figure 2C). Figure S1A shows a similar result
obtained in a replicate experiment. Similarly, in non-adherent cell
cultures in soft agar, the A549/146b and A549/v146b formed
significantly less colonies than A549/vec (57% and 74%, with t test
P values of 0.02 and ,0.01, respectively), but the sizes colonies were
of similar sizes (t test P values of .0.05; figure 2D). There was no
significant difference between the colony formation abilities of
A549/146b and A549/v146b. Figure S1B shows a similar result
obtained in a replicate experiment.
Migration of the cells was assessed in two different types of
assays: an in vitro wound healing assay to test the ability of a cell
monolayer to close a gap created by a scratch, and a transwell
assay to test the movement of serum-starved cells towards serum-
rich medium. In neither assay was the ability of A549/146b or
A549/v146b cells significantly different from that of A549/vec, or
each other, indicating a lack of an effect of miR-146b overexpres-
sion on migration of A549 cells (t test P values of .0.05; figure 3A
and 3B). Figures S1C and S1D show similar results obtained in
replicate experiments. Similar observations were obtained from
invasion assays which examined the capability of serum-starved
cells to move to serum-rich medium by invading through a layer of
extracellular matrix made of either rat collagen I or murine
basement membrane extract (figure 3C). Figure S1E and S1F
show similar results obtained in replicate experiments. The ability
Figure 2. Proliferation of the A549-derived cell-lines. A. Cell density was indirectly assessed by a colorimetric assay for cell viability.
Absorbance values at 450 nm with increasing hours of cell culture are shown. B. Effect on cell density following treatment with 0.5, 1.0 or 2.0 ug/ml
cisplatin (Cis.) or doxorubicin (Dox.) for 2 days. Absorbance values at 450 nm obtained with a colorimetric cell viability assay are shown. C, D. Number
and average areas of colonies seen in adherent (C) or non-adherent (D) culture on tissue culture plates or in soft agar, respectively. Two hundred (C)
or 150 (D) cells were seeded per culture and colonies were quantified after two (C) or six (D) weeks. Means and their standard errors for triplicates (A,
C, D) or quintuplicates (B), from one of three experiments with similar results for A, C and D, are shown.
doi:10.1371/journal.pone.0022379.g002
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experiment, in an in vivo setting in which the cells were
intravenously injected in immunodeficient female mice (five
animals for each cell-line), and tumor formation by the cells in
the lungs of the mice was examined after 12 weeks. Though none
of the mice had exhibited any symptom suggestive of pulmonary
tumor formation, such as labored breathing, the period of 12
weeks was chosen based on other studies that used a method
similar to the one used here and reported presence of gross
pulmonary tumors after injection of A549 cells [24]. Multiple
tumors of .1 mm diameter were visible to the naked eye on the
outer surface of the lungs in 11 of the 15 mice. Red fluorescence
of the tumors indicated that they were derived from the injected
cells. However, a significant difference between the lung tumor
formation abilities of three lines could not be discerned by such
visual examination, or by weighing the lungs (t test P values of
.0.05; figure 4A). No tumors on the surface of other thoracic or
abdominal organs, or in the linings of the thoracic or abdominal
cavities were visible to the naked eye in any of the mice.
miR-146b overexpression altered the expression of only a
few genes in A549/146b cells
A549/vec and A549/146b cells of similar age in culture were
concurrently grown to semi-confluence on two different occasions
for isolating total RNA. A high-density bead-array platform
(IlluminaH BeadChips
TM) was used to quantify about 25,000
mRNA transcripts in the RNA preparations to obtain two pairs of
gene expression profiles. Forty-three% and 38% of the transcripts
were considered as expressed, respectively, in at least one or all four
profiles. Pearson correlation coefficients for all expression values for
the two biological duplicates for each cell-line were .0.99. Paired
comparison of the expression values using moderated t statistics and
Benjamini-Hochbergcorrection forfalsediscoveryshowedthat only
33 transcripts, about 0.3% of expressed mRNA transcripts, were
differentially expressed in A549/146b, with 16 down-regulated
30%–50% and 17 up-regulated 50%–140% (table S1). The March
2011 release of the comprehensive miRWalk database of validated
and predicted microRNA targets [25] was searched to find out if
any of the differentially expressed transcripts was a predicted target
of miR-146b-5p or -3p (table S1). Nine (56%) of the 14 down-
regulated known mRNAs were predicted to be a target of at least
one of the two microRNAs as per at least one of the following nine
microRNA target prediction algorithms: Diana-microT, miRanda,
miRDB, miRWalk, PICTAR5, PITA, RNA22, RNAhybrid and
Figure 3. Migration and invasion assays of the A549-derived
cell-lines. A. Migration of cells in an in vitro wound-healing assay is
depicted as a reduction in the width of a scratch across a monolayer of
cells after a day of culture. B. Migration of serum-starved cells towards
15% serum-containing medium through an 8 mm pore-sized polycar-
bonate membrane after 8 hours of culture. Migrated cells were fixed
and stained with crystal violet, and indirectly quantified by measuring
absorbance of extracts of cell stains at 595 nm. C. Like B, but with
membranes coated with a murine basement membrane extract (BME)
or rat collagen I, and culture for 16 hours. Migrated cells were imaged
by red fluorescence microscopy at 5x magnification. Means and their
standard errors for triplicates from one of three experiments with
similar results are shown.
doi:10.1371/journal.pone.0022379.g003
Figure 4. Lung colony formation by the A549-derived cell-lines,
and miR-146b expressions in tumor stroma and epithelia. A.
Generation of pulmonary tumors by intravenous injection of the A549-
derived cell-lines. A million cells per animal were injected in the tail
veins of young female immunodeficient mice. After 12 weeks, animals
were dissected and both of their lungs weighed. Five mice were used
for each cell-line. B. Relative expression of let-7e, miR-30a-5p, and miR-
146b-5p and -3p microRNAs in stromal and cancerous epithelial
components of stage I non-small cell lung cancer as assessed using
reverse transcription followed by PCR. Stroma and epithelia were
microdissected using tumor sections from 12 cases of the disease.
Levels are normalized to that of the RNU6B small nucleolar RNA. Means
and their standard errors are shown. MicroRNA miR-146b-3p was
detectable in both compartments of only 11 tumors. Only four tumors
were used for let-7e quantification.
doi:10.1371/journal.pone.0022379.g004
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regulated mRNAs were also predicted to be a miR-146b target.
Expression of miR-146b microRNAs is higher in stroma
than in epithelia in stage I NSCLC
In the studies in which the miR-146b microRNAs in early stage
NSCLC were quantified [3,4], the analyzed RNA was obtained
from whole tumor. Besides cancerous epithelial cells, tumors have
stromal cells which are not cancerous but which do express
microRNAs, and which have an influence on the biological
behavior of the cancerous cells of the tumors. To characterize the
expression of miR-146b in the stromal and epithelial components
of NSCLC, a section each from 12 stage I tumors was used for
microdissecting and separating the components with LCM. Figure
S2 illustrates the microdissection of tumor epithelia and stroma for
two of the 12 tumors. Eight of the tumors were squamous cell
carcinomas, three were adenocarcinomas, and one was bronch-
ioloalveolar carcinoma. MicroRNA expression values in the two
components were compared after normalization to that of RNU6B
(figure 4B). In all 12 tumors, expression of miR-146b-5p was
significantly higher in the stromum than in the epithelium (average
and range of 7.0- and 1.8-24.1-fold; t test P,0.01). In the 11
tumors in which miR-146b-3p was detected in both compartments,
expression of miR-146b-3p too was higher in the stromum than in
the epithelium (average and range of 10.4- and 0.4–25.1-fold,
respectively; t test P,0.01). Such relatively high stromal/epithelial
expression ratios were not observed for miR-30a-5p (average and
range of 1.5- and 0.1–4.8-fold, respectively; t test P=0.95) and let-
7e (average and range of 1.7- and 1.0–2.2-fold, respectively; t test
P=0.18), two other microRNAs known to be expressed in
NSCLC [3].
Prognostic value of miR-146b expression in stage I NSCLC
We analyzed microarray-based quantifications of miR-146b-5p
and -3p in a microRNA expression dataset previously obtained by
us for RNA from formalin-fixed, paraffin-embedded tumor tissue
from 77 cases of stage IA NSCLC. Thirty-seven (48%) of the cases
had a recurrence of the disease following resective surgery while
the remaining 40 did not during the minimum of 32 months for
which they were followed. MicroRNA expression profiles of their
NSCLC tissues were obtained to test the association of recurrence
with microRNA alterations, and to generate microRNA classifiers
capable of predicting recurrence [3]. MicroRNA miR-146b-5p was
identified as a component of the multi-variable predictive
classifiers in that study. We now specifically compared the
expression of miR-146b-5p and -3p microRNAs, and their ratio,
in patients with recurrence to those without. Using the median
values of the three variables as cut-off, we also performed survival
analyses. As shown in figure 5A, the expression level of miR-146b-
5p was significantly higher (average 1.53-fold; t test P,0.01)
among the cases with recurrence than in those without. However,
the expression level of miR-146b-3p was significantly lower
(average 0.84-fold; t test P,0.01). The ratio of miR-146b-5p and
-3p expression levels was also significantly different between the
two case-groups, it being an average of 1.67-fold higher in cases
with recurrence (t test P ,0.01). Kaplan-Meier survival analyses
using group medians for cut-off showed that all three parameters
had prognostic value for predicting recurrence of the disease
following surgery. High miR-146b-5p expression, low miR-146b-3p
expression, and high miR-146b-5p/-3p ratio were associated with
hazard ratios of 2.23 (95% confidence interval [CI] =1.14–4.34),
3.91 (95% CI=1.99–7.68), and 2.95 (95% CI=1.50–5.82), with
Mantel-Cox log-rank test P values of 0.02, ,0.01, and ,0.01,
respectively (figure 5B). Thus, the two miR-146b microRNAs were
found to have opposite prognostic values.
Discussion
The expression of miR-146b microRNAs in NSCLC has been
associated with prognosis of the disease [3,4]. We attempted to
explore the biological bases of this association by studying the
functional consequences of miR-146b overexpression on the
malignant nature of the A549 lung adenocarcinoma cell-line.
Because tumors in NSCLC with a poor prognosis have higher
miR-146b-5p expression [3,4], A549 cells overexpressing miR-146b
microRNAs were expected to have a more malignant behavior.
However, an opposite, though minimal, effect of miR-146b
Figure 5. Expression of miR-146b-5p and -3p in a set of 77 cases
of stage I non-small cell lung cancer. A. Scatter-plots of microarray
signal intensities, relative to that for a reference RNA, for miR-146b-5p or
-3p, or their ratio, for RNA from resected tumor tissue from 37 cases
with recurrence of the disease, and for 40 cases without recurrence
during the $32 months of follow-up following surgery [3]. Means and
their standard errors are shown. B. Kaplan-Meier plots depicting post-
resection recurrence-free survival among the case-groups with values of
miR-146b-5p or -3p, or their ratio, lower (low, grey line) or higher (high)
than the group median. Hazard ratios (HR) and time in months to
recurrence following surgery are shown. Tick-marks along the lines
indicate right-censored data-points.
doi:10.1371/journal.pone.0022379.g005
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different A549 overexpressor cell-lines used in this study, A549/
146b and A549/v146b, had similar cellular proliferation,
chemosensitivity to cisplatin or doxorubicin, and migration and
invasiveness both in vivo and in vitro as the A549/vec control cells
(figures 2A-4A), they formed about a quarter less colonies in
adherent as well as non-adherent cell culture (figures 2C and 2D).
Such inhibitory effect of miR-146b microRNAs on a cell’s
malignant phenotype has been demonstrated for breast cancer
and glioblastoma cells in studies that found dramatic effects of
miR-146b overexpression or inhibition on cell migration and
invasiveness [18,19,20,21]. The absence of an effect on cell
migration and invasiveness in this study (figures 3A-4A) could be
because of differences between the cell-lines used in the studies.
Among lung cancer cell-lines, A549 cells are considered as highly
invasive [26], and it is possible that an effect of miR-146b
overexpression on cell migration and invasiveness could not be
observed because of this. The effects on cell migration and
invasiveness seen in the other studies could also be because of the
higher degree of miR-146b-5p overexpression that was achieved in
the other studies. The ,2.6-6.6-fold overexpression of the miR-
146b microRNAs in this study is, however, similar to or higher
than the general degree of overexpression seen when comparing
microRNA profiles of NSCLC tumors with different prognoses
[3,4] (figure 5A).
Examination of gene expression profiles of the A549/vec and
A549/146b cells showed that only about 0.3% of the cells’
transcriptome was affected by the overexpression of the miR-146b
microRNAs (table S1). This small fraction appears to be consistent
with the observation that A549/vec and A549/146b cells behaved
similarly in almost all the assays for cell phenotype that were
conducted in this study. We were unable to fathom a connection
between the gene expression changes and the reduced ability of
A549/146b cells to form colonies in vitro (figures 2C and 2D).
More than half of the down-regulated transcripts were predicted to
be miR-146b targets (table S1), which is consistent with the fact that
microRNAs induce target mRNA degradation [27]. A majority of
the up-regulated transcripts, too, were predicted to be miR-146b
targets (table S1). It is possible that the increased levels of these
transcripts are a distant effect of miR-146b overexpression or
reflect different genomic changes in the A549/vec and A549/146b
cells during generation of the engineered cell-lines. Many of the
up-regulated transcripts are associated with cancer biology; e.g.,
ADAM19 [28] and CDH2 [29]. It is interesting that the products
of many of the up-regulated transcripts, like ABCA1, GOLT1B and
SLC30A7, participate in cellular trafficking of molecules.
The negative association of miR-146b-5p levels and malignant
nature of cells seen in this and the other cell-line-based studies
appears to contradict the observation of higher miR-146b-5p
expression in tumors with poor prognosis [3,4,5]. In the cell-line
studies, miR-146b-5p overexpression was achieved using expression
vectors for pre-miR-146b, which is also the precursor for miR-146b-
3p. Because of this, the level of miR-146b-3p too gets higher in the
overexpressor cells (figure 1C), and this can affect the influence of
miR-146b-5p overexpression on the cells. As depicted in figure 5, the
prognostic values associated with miR-146b-5p and -3p microRNAs
appear to be antagonistic, with higher miR-146b-5p levels but lower
miR-146b-3p levels in stage I NSCLC tumors associated with disease
recurrence following surgical resection. It is thus possible that two
microRNAs have opposing effects on the malignant phenotype of
cancerous cells, and the effects seen in the cell-line-based studies
reflect the net effect of having higher levels of both of them. As per
the MicroCosm database of predicted targets of microRNAs
(http://www.ebi.ac.uk/enright-srv/microcosm) generated using the
miRanda 3.0 algorithm [30], 941 and 943 human transcripts,
respectively, are targeted by miR-146b-5p and -3p, with only 75
targeted by both. Finally, as has been seen in many studies
[31,32,33], it is possible that the prognostic values of the two
microRNAs actually resides within microRNA expression changes
in the non-cancerous stroma of the NSCLC tumors. Both miR-146b-
5p and -3p microRNAs appear to be expressed much more in the
stromathaninthecancerousepitheliaofNSCLCtumors(figure4B).
It should be noted that the miR-146b microRNAs are expressed well
in cells of the hematopoietic system [34,35,36]. A549 is an
adenocarcinoma cell-line whereas in the studies identifying the
prognostic value of miR-146b microRNAs in NSCLC, the tumors
were either only squamous cell carcinomas [4] or included
squamous cell carcinomas and bronchioloalveolar carcinomas
besides adenocarcinomas [3]. It might be that the absence of a
major effect of miR-146b overexpression on A549 cells reflects the
possibility that miR-146bexpressiondoesnot havea prognostic value
in NSCLC of adenocarcinoma histology.
MicroRNA overexpression in cells is routinely performed using
pre-microRNAs which are produced endogenously from expres-
sion constructs or introduced exogenously synthesized and
introduced in cells using techniques like RNA transfection.
However, because such precursor RNAs give rise to not one but
two mature microRNAs from the two strands of the duplex RNA
stem of the molecules, as seen in this study, the interpretation of
results can be difficult. Engineering the expression of only one of
the two microRNAs, or the overexpression of one relative to the
other, using precursor RNAs has not been described. Among
human microRNAs, 5p microRNAs tend to be expressed more
than 3p ones [11], and we sought to achieve relative overexpres-
sion of miR-146b-3p by using a variant pre-miR-146b pre-
microRNA in which the segments of the molecule for the 5p
and 3p microRNAs were swapped (figure 1A). However, this
strategy was unsuccessful (figure 1E). Specific functional overex-
pression of either the 5p or the 3p microRNA may be possible
using pre-microRNAs that have mutations in the sequence of one
of the two microRNAs, or at positions that affect pre-microRNA
processing [37]. Strand-specific 59 O-methylation or biaryl
modification of microRNA duplexes may also be used for 5p- or
3p-specific overexpression [38,39]. Specific knockdown of a 5p
microRNA without affecting its 3p sibling may be achievable using
antisense oligonucleotides [40] or microRNA sponges [41].
However, there are different issues such as antisense effects on
pre-microRNA processing, non-specificity, and durability of
knockdown that are associated with these methods.
In conclusion, we found that overexpression of the lung cancer
prognostic miR-146b microRNAs diminishes the malignant pheno-
type of the A549 lung cancer cells. This effect was minimal and
opposite of that expected from tumor microRNA expression
profiles. The study highlights the myriad issues that impede the
elucidation of biological roles of microRNAs and their correlations
with observations obtained in tumor microRNA expression studies.
Supporting Information
Figure S1 Results of replicate experiments. Results of one
replicate experiment each for the sets of experiments whose results
are presented in figures 2C (A, adherent colony formation), 2D (B,
colony formation in soft agar), 3A (C, in vitro wound-healing), 3B
(D, Transwell
TM migration), 3C (E, invasion through murine
basement membrane extract) and 3D (F, invasion through rat
collagen I). The details provided in the legends of those figures are
true for the ones here as well.
(TIF)
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lia. Photomicrographs of hematoxylin-eosin-stained sections of
two non-small cell lung carcinoma tumors (1 and 2) before laser
microdissection (A), after microdissection of tumor epithelia (B)
and after additional microdissection of tumor stroma adjacent to
the dissected epithelia (C). Both tumors are squamous cell
carcinomas. Tumor epithelia and stroma were identified by
histology. Red and blue outlines seen on the images show the
enclosed tissue areas that were dissected. Each bar in the scale
below is indicates 400 um.
(TIF)
Table S1 mRNA transcripts differentially expressed in
A549/vec and A549/146b cells.
(DOC)
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